Abivax S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,308.20
2,923.60
39,127.00
22,987.00
17,032.00
13,002
Total Accounts Receivable
2,245.60
2,389.30
3,909.00
4,803.00
3,646.00
7,774
Inventories
20.60
-
-
-
-
-
Other Current Assets
26.00
327.10
118.00
51.00
198.00
201
Total Current Assets
5,600.40
5,640.00
43,154.00
27,841.00
20,876.00
20,977
Net Property, Plant & Equipment
66.10
230.60
171.00
191.00
202.00
151
Total Investments and Advances
-
-
935.00
560.00
732.00
180
Long-Term Note Receivable
42.10
86.30
-
-
-
735
Intangible Assets
32,754.30
32,009.10
32,008.00
32,005.00
32,005.00
32,005
Total Assets
38,463.00
37,966.00
76,268.00
60,597.00
53,815.00
54,048
ST Debt & Current Portion LT Debt
-
-
-
170.00
170.00
Accounts Payable
1,561.80
1,049.70
2,808.00
2,571.00
-
Other Current Liabilities
3,084.00
4,124.20
916.00
976.00
5,342.00
Total Current Liabilities
4,645.90
5,173.90
3,724.00
3,717.00
5,512.00
Long-Term Debt
2,320.50
2,089.50
3,414.00
2,354.00
92.00
Provision for Risks & Charges
-
49.20
371.00
16.00
27.00
Other Liabilities
-
-
-
-
4,268.00
Total Liabilities
6,966.30
7,312.60
7,509.00
6,087.00
9,899.00
Common Equity (Total)
31,496.70
30,653.40
68,759.00
54,510.00
43,916.00
Total Shareholders' Equity
31,496.70
30,653.40
68,759.00
54,510.00
43,916.00
Total Equity
31,496.70
30,653.40
68,759.00
54,510.00
43,916.00
Liabilities & Shareholders' Equity
38,463.00
37,966.00
76,268.00
60,597.00
53,815.00

About Abivax

View Profile
Address
5, rue de la Baume
Paris Ile-de-France 75008
France
Employees -
Website http://www.abivax.com
Updated 07/08/2019
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis.